SEC Form 5 · accession 0001078782-17-000216
AXIM BIOTECHNOLOGIES, INC. · AXIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Anastassov
Officer — CEO/Secretary · Director · 10% Owner
Period of report
Dec 31, 2016
Accepted (ET)
Feb 15, 2017 · 7:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001514946
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 21, 2016 | A | 250,000 | $0.00 | A | 3,002,000 | D | |
| Common StockF1 | Nov 21, 2016 | A | 2,000,000 | $0.00 | A | 3,002,000 | D | |
| Preferred StockF2 | Nov 21, 2016 | A | 500,000 | $0.00 | A | 500,000 | I | See footnote 2 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 3,626,706 shares of common stock. Mr. Anastassov is an affiliate and control person of Sanammad Foundation USA which holds 14,613,650 shares of common stock.
- F2Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 500,000 shares of Series B preferred stock.